Last reviewed · How we verify
NCT03156699
The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
trial in ST Elevation Myocardial Infarction in 64 participants. Completed in 30 May 2018.
1 May 2018
Quick facts
| Lead sponsor | The Royal Wolverhampton Hospitals NHS Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 September 2017 |
| Primary completion | 1 May 2018 |
| Estimated completion | 30 May 2018 |
| Sites | 1 location across United Kingdom |
Conditions studied
- ST Elevation Myocardial Infarction — all drugs for ST Elevation Myocardial Infarction →
Sponsor
The Royal Wolverhampton Hospitals NHS Trust
Who can join
Eligibility, any sex, with ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the incidence, effect and persistence of F-QRS (Fragmented-QRS) in STEMI (ST-elevation Myocardial Infarction) patients post-PCI (percutaneous coronary intervention). The aim is to add to the existing research field surrounding F-QRS. It is hypothesised that patients with F-QRS present on the surface ECG, following PCI, will have incurred a higher degree of damage. As a result, it is hypothesised that these patients will have reduced LV (left-ventricular) systolic function, increased incidence of regional wall motion abnormalities (RWMAs), and increased troponin levels on admission. This study will additionally look for correlations between F-QRS and culprit vessels. To our knowledge there is minimal research regarding this.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03156699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ST Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT05785897 — STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT · NA · recruiting
- NCT06795035 — Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution · recruiting
- NCT07058857 — The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocard · NA · recruiting
- NCT06465303 — A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEM · Phase 2 · recruiting
- NCT06535503 — Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City · recruiting
Other The Royal Wolverhampton Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT06581757 — Serum GFAP and UCHL1: Evaluation of Their Predictive Value for SAH · terminated
- NCT04741230 — Investigator Initiated, Prospective Study of Xenia Corneal Lenticule · NA · recruiting
- NCT05434949 — Pre-analytical Influences on a Blood Test Study · completed
- NCT05196815 — Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aorti · NA · completed
- NCT05177484 — Perioperative Iron for Colorectal Cancer (PICoC Study) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03156699 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Royal Wolverhampton Hospitals NHS Trust
- Last refreshed: 18 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03156699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing